ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PACB vs NAUT // ALTMAN Z-SCORE & DEBT/EQUITY

Pacific Biosciences of California Inc. (NASDAQ) VS. Nautilus Biotechnology Inc. (NASDAQ) • 15-METRIC TALLY: PACB 3 — NAUT 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PACB VS. NAUT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PACB NAUT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 28.60% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -12.64% -12.99% +0.35 PACB /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 61.4 57.4 +3.95 PACB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $901.4M $399.9M $501.5M PACB /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PACB REV NAUT REV PACB GROSS % NAUT GROSS % PACB FCF NAUT FCF
FY 2025 $160.0M $0 28.6% — -$113.9M -$52.0M
FY 2024 $154.0M $0 24.2% — -$212.2M -$61.3M
FY 2023 $0 $0 — — -$259.2M -$51.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PACB // BETA —
NAUT // BETA —